Computational pathological identification of prostate cancer following neoadjuvant treatment.

Belma Dogdas, Christopher Kanan, Patricia Raciti, Shaozhou K. Tian, Sabine Brookman‐May, Lisa Wetherhold, Alexis K. Smith, Oliver Brendan Rooney, Sharon McCarthy, John Alvarez, Angela Lopez‐Gitlitz, Adam Casson, Ran Godrich, Jeremy D. Kunz, Rodrigo Ceballos, Carla Leibowitz, Leo Grady, Thomas J. FuchsJournal of Clinical Oncology 2020 · DOI

Abstract

e14052 Background: The need for accurate pathological identification and quantitation of prostate cancer (PC) following neoadjuvant treatment with androgen deprivation therapy (ADT) and androgen receptor antagonists is increasing as PC treatment continues to evolve. In clinical practice, pathological assessment of residual tumor is a tedious and time-consuming process due to the volume of tissue from radical prostatectomy (RP). In addition, neoadjuvant treatments can greatly alter both benign and neoplastic prostate tissue morphology making the pathology assessment difficult for even specialized pathologists. Paige Prostate 1.0 is a clinical-grade artificial intelligence (AI) system for PC detection. It was trained and evaluated in over 50,000 prostate biopsy slides with validation across more than 800 institutions worldwide using multiple slide scanners. Methods: We evaluated the performance of Paige Prostate 1.0 at identifying prostatic tumor on 64 hematoxylin and eosin stained slides exhibiting neoadjuvant treatment effect from apalutamide, enzalutamide, and/or ADT. Results: Analysis of the receiver operating characteristic curve demonstrated an area under the curve of 0.96. Using the Paige Prostate 1.0 operating point, it achieved a sensitivity of 91% and a specificity of 94%, corresponding to the correct identification of challenging treated morphology in 59/64 slides using expert pathologists as the reference. False negative cases were typically represented by atypical small acinar proliferation that required expert pathological consensus confirmation. Conclusions: To our knowledge, this is the first AI based evaluation of residual disease in PC with hormone neoadjuvant therapy. Paige Prostate 1.0 effectively identified tumor despite treatment effects. Future work will include optimization of Paige Prostate 1.0 by training with RP specimens from a larger cohort of appropriate samples, as well as precise measurement of residual tumor burden to further improve its accuracy and reproducibility. Paige prostate residual disease detection 1.0 has the potential to impact emerging clinical practice at the patient level and to complement the pathological assessment of RPs in global phase 3 clinical trials, such as PROTEUS, in a standardized, reproducible, and robust way.
BibTeX
@article{dogdas2020computational,
  author = {Belma Dogdas and Christopher Kanan and Patricia Raciti and Shaozhou K. Tian and Sabine Brookman‐May and Lisa Wetherhold and Alexis K. Smith and Oliver Brendan Rooney and Sharon McCarthy and John Alvarez and Angela Lopez‐Gitlitz and Adam Casson and Ran Godrich and Jeremy D. Kunz and Rodrigo Ceballos and Carla Leibowitz and Leo Grady and Thomas J. Fuchs},
  title = {{Computational pathological identification of prostate cancer following neoadjuvant treatment.}},
  journal = {Journal of Clinical Oncology},
  year = {2020},
  doi = {10.1200/jco.2020.38.15\_suppl.e14052},
}

Loading related content...

Figure